The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Approaching the treatment of patients with LBCL who relapse after bispecific antibodies
Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the critical challenges faced by patients with large B-cell lymphoma (LBCL) who relapse after treatment with bispecific antibodies. These patients often present with peripheral cytopenia and neutropenia, as well as genetic changes and loss of CD19 and CD20 expression. Prof. Carlo-Stella emphasizes the need to develop new treatments targeting different markers due to the ineffectiveness of current CD20 and CD19 therapies in these cases. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
